PerkinElmer CEO Cites Cell Screening Technologies as ‘Acquisition Priorities’
Recognizing the recent increased uptake of cell-based assays in drug discovery, a high-ranking PerkinElmer official last week said the company has made cellular screening technologies and related consumables and reagents “acquisition priorities,” and that it will continue to build out its cell-based screening platforms, particularly in the areas of GPCRs and kinases.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.